Oral Bacteria May Diagnose Pancreatic Cancer
|
By LabMedica International staff writers Posted on 04 Jun 2014 |

Image: The anaerobic bacteria Leptotrichia species, Gram-stain from blood culture (Photo courtesy of Mike Dyall-Smith).
Patients with pancreatic cancer have a different and distinct profile of specific bacteria in their saliva compared to healthy controls and even patients with other cancers or pancreatic diseases.
Patients diagnosed in the early stages of pancreatic cancer have a 5-year survival rate of 21.5%, but unfortunately symptoms do not appear until after the cancer has become untreatable in the vast majority of cases.
Scientists from San Diego State University (CA, USA) compared the diversity of saliva bacteria across 131 patients, 63 females and 68 males, being treated at the University of California, San Diego (UCSD) Moores Cancer Center (La Jolla, CA, USA). Of these patients, 14 had been diagnosed with pancreatic cancer, 13 with pancreatic disease, 22 with other forms of cancer, and 10 were disease free.
The results of the study found that patients diagnosed with pancreatic cancer had higher levels of two particular oral bacteria, Leptotrichia and Campylobacter, when compared to any other healthy or diseased state including noncancerous pancreatic disease. Those with pancreatic cancer also had lower levels of Streptococcus, Treponema, and Veillonella. These findings could form the basis for a test to diagnose the pancreatic cancer in its early stages.
Pedro Torres, BS, the coauthor of the study with Scott T. Kelley, PhD, said, “Our studies suggest that ratios of particular types of bacteria found in saliva may be indicative of pancreatic cancer. The results also suggest the presence of a consistently distinct microbial profile for pancreatic cancer. We may be able to detect pancreatic cancer at its early stages by taking individuals’ saliva and looking at the ratios of these bacteria.”
In the USA, approximately 40,000 people die every year due to pancreatic adenocarcinoma, making it the fourth leading cause of cancer related death. The study was presented on May 18, 2014, at the Annual meeting of the American Society for Microbiology held May 17–20, 2014, in Boston (MA, USA).
Related Links:
San Diego State University
Moores Cancer Center
Patients diagnosed in the early stages of pancreatic cancer have a 5-year survival rate of 21.5%, but unfortunately symptoms do not appear until after the cancer has become untreatable in the vast majority of cases.
Scientists from San Diego State University (CA, USA) compared the diversity of saliva bacteria across 131 patients, 63 females and 68 males, being treated at the University of California, San Diego (UCSD) Moores Cancer Center (La Jolla, CA, USA). Of these patients, 14 had been diagnosed with pancreatic cancer, 13 with pancreatic disease, 22 with other forms of cancer, and 10 were disease free.
The results of the study found that patients diagnosed with pancreatic cancer had higher levels of two particular oral bacteria, Leptotrichia and Campylobacter, when compared to any other healthy or diseased state including noncancerous pancreatic disease. Those with pancreatic cancer also had lower levels of Streptococcus, Treponema, and Veillonella. These findings could form the basis for a test to diagnose the pancreatic cancer in its early stages.
Pedro Torres, BS, the coauthor of the study with Scott T. Kelley, PhD, said, “Our studies suggest that ratios of particular types of bacteria found in saliva may be indicative of pancreatic cancer. The results also suggest the presence of a consistently distinct microbial profile for pancreatic cancer. We may be able to detect pancreatic cancer at its early stages by taking individuals’ saliva and looking at the ratios of these bacteria.”
In the USA, approximately 40,000 people die every year due to pancreatic adenocarcinoma, making it the fourth leading cause of cancer related death. The study was presented on May 18, 2014, at the Annual meeting of the American Society for Microbiology held May 17–20, 2014, in Boston (MA, USA).
Related Links:
San Diego State University
Moores Cancer Center
Latest Pathology News
- FDA Clears AI Digital Pathology Tool for Breast Cancer Risk Stratification
- New AI Tool Reveals Hidden Genetic Signals in Routine H&E Slides
- AI System Analyzes Routine Pathology Slides to Predict Cancer Outcomes
- New Tissue Mapping Approach Identifies High-Risk Form of Diabetic Kidney Disease
- Multimodal AI Tool Predicts Genetic Alterations to Guide Breast Cancer Treatment
- Interpretable AI Reveals Hidden Cellular Features from Microscopy Images
- Tumor Immune Structure Predicts Response to Immunotherapy in Melanoma
- Plug-and-Play AI Pathology System Classifies Multiple Cancers from Few Slides
- AI-Based Assays Support Risk Stratification in Prostate and Breast Cancer
- AI Pathology Model Predicts Immunotherapy Response in Lung Cancer
- Study Reveals Moleclar Mechanism Driving Aggressive Skin Cancer
- AI Precision Tests Deliver Cancer Risk Insights from Routine H&E Slides
- Collaboration Applies AI Pathology to Predict Response to Antibody-Drug Conjugates
- Biomarker Predicts Immunotherapy Response and Prognosis in Colorectal Cancer
- AI Improves Completeness of Complex Cancer Pathology Reports
- AI Tool Predicts Chemotherapy Response in Small Cell Lung Cancer
Channels
Clinical Chemistry
view channel
Ultrasensitive Test Detects Key Biomarker of Frontotemporal Dementia Subtype
Dementia affects more than 57 million people worldwide and is projected to nearly double within two decades, straining health systems and families. While biomarkers now enable accurate identification of... Read more
Routine Blood Tests Years Before Pregnancy Could Identify Preeclampsia Risk
High blood pressure during pregnancy is common and can progress to pre-eclampsia, making close monitoring at antenatal visits essential. However, most risk assessment begins only after pregnancy has started.... Read moreMolecular Diagnostics
view channel
Blood Test Maps Tumor Microenvironment to Predict Immunotherapy Response
Immunotherapy has transformed cancer care, yet durable benefit remains limited to a subset of patients, and clinicians still lack reliable tools to predict response before treatment begins.... Read more
Multiplex Respiratory Panel Integrates Automated Extraction to Streamline High-Volume Testing
Respiratory infections drive heavy testing volumes in clinical laboratories, where accurate, timely results across multiple pathogens are essential. Many labs are seeking to streamline workflows and increase... Read more
Whole-Blood RNA Test Predicts Disease Trajectory and Treatment Response
Clinicians often must predict whether acutely ill patients will recover or deteriorate despite limited time and clinical evidence. Earlier prognostic information could improve triage and guide treatment... Read more
Blood-Based Epigenetic Test Predicts GLP-1 Response and Tracks Treatment Effects
Prescriptions for GLP-1 medicines for weight loss are expanding rapidly, yet clinicians still lack scalable tools to predict biological response before treatment or monitor drug-driven changes beyond the scale.... Read moreHematology
view channel
Advanced CBC-Derived Indices Integrated into Hematology Platforms
Diatron, a STRATEC brand, has introduced six advanced hematological indices on its Aquila, Aquarius 3, and Abacus 5 hematology analyzers. The new Research Use Only (RUO) indices include Neutrophil-to-Lymphocyte... Read more
Blood Test Enables Early Detection of Multiple Myeloma Relapse
Bone marrow biopsies remain central to diagnosing and monitoring multiple myeloma, yet the procedure is painful, invasive, and often repeated over time. Older patients—who represent most new cases—can... Read moreImmunology
view channel
Point-of-Care Tests Could Expand Access to Mpox Diagnosis
Mpox outbreaks in non-endemic regions have underscored the need for rapid, accessible diagnostics to limit transmission. Polymerase chain reaction (PCR) remains the clinical reference, yet it depends on... Read more
T-Cell Senescence Profiling May Predict CAR T Responses
Chimeric antigen receptor (CAR) T-cell therapy can deliver striking, durable remissions, yet many patients experience minimal or no benefit. The quality of patient-derived cytotoxic T lymphocytes used... Read morePathology
view channel
FDA Clears AI Digital Pathology Tool for Breast Cancer Risk Stratification
Risk assessment at diagnosis is central to guiding therapy for early-stage, hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) invasive breast cancer, where overtreatment... Read more
New AI Tool Reveals Hidden Genetic Signals in Routine H&E Slides
Pathologists worldwide rely on hematoxylin and eosin (H&E) slides to examine tissue architecture, yet these stains do not reveal the underlying molecular activity that often drives disease.... Read moreTechnology
view channel
Tumor-on-a-Chip Platform Models Pancreatic Cancer Treatment Response
Pancreatic cancer remains one of the hardest malignancies to treat because tumors are embedded within a dense microenvironment that shapes growth and therapy response. Standard laboratory models often... Read more
New Platform Captures Extracellular Vesicles for Early Cancer Detection
Early diagnosis remains the most effective way to reduce cancer mortality, yet many screening tools miss disease at its earliest stages. Biomarkers shed by tumors into blood and other fluids can be scarce... Read moreIndustry
view channel








